GLOSTRUP, DENMARK--(Marketwired - April 03, 2013) - Dako, an Agilent Technologies Company and
worldwide provider of cancer diagnostics, recently received clearance from
U.S. Food and Drug Administration to sell FLEX Monoclonal Rabbit Anti-Human
Estrogen Receptor alpha, Clone EP1 in the United States. The clone has
available in Europe for some time and has enjoyed widespread acceptance.
"We are very pleased to now be able to supply our customers in the United
with this high-quality antibody for estrogen receptor testing on Dako's
Autostainer Link 48," said Karen Balstrup, global product manager, IHC
Research has shown that tumor growth is dependent on the presence of
progesterone or both in most breast cancers. Estrogen receptor (ER) status
breast carcinomas is a validated prognostic and predictive factor for
patient's anti-hormonal therapy. With this important diagnostic tool from
breast cancer patients can be confident they are receiving the most
treatment for their particular type of breast cancer.
Clone EP1 shows excellent concordance with the existing ER component from
ER/PR pharmDx Kit, with an overall agreement of 97.7 percent, a strong
indication that pathologists can rely on the results obtained from using
"Clone EP1 specifically detects nuclear estrogen receptor without
staining and shows a high degree of concordance (greater than 95 percent)
existing clones," said Sunil S. Badve, M.D., Department of Pathology and
Laboratory Medicine, Indiana University. "Compared with other established
antibody assays this new clone is a highly sensitive and specific
The Monoclonal Rabbit Anti-Human ER alpha, Clone EP1 was created by
Inc., using Epitomics' proprietary rabbit monoclonal antibody technology
under Patent Nos. 5,675,063 and 7,402,409. Dako and Epitomics entered into
collaboration in 2011 which allows the companies to unite competencies to
provide the anatomic pathology market with state-of-the-art antibodies.
About Dako - An Agilent Technologies Company
Dako, based in Denmark, is a global leader in tissue-based cancer
Hospital and research laboratories worldwide use Dako's reagents,
software and expertise to make accurate diagnoses and determine the most
effective treatment for cancer patients. Dako, with 1,200 employees,
more than 100 countries. Dako became part of Agilent Technologies on June
21, 2012. Information about Dako is available at www.dako.com.
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is the world's premier measurement
and a technology leader in chemical analysis, life sciences, diagnostics,
electronics and communications. The company's 20,500 employees serve
in more than 100 countries. Agilent had revenues of $6.9 billion in fiscal
2012. Information about Agilent is available at www.agilent.com.
Press Release pdf:
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Dako Denmark A/S via Thomson Reuters ONE